86 results about "Therapy resistant" patented technology

The invention discloses a method for predicting the clinical outcome of treatment of a CRSwNP patient by omphizumab according to the baseline expression level of cytokines in nasal secretions and application of the method. 48 cytokines in the nasal secretions of the patient are detected before treatment by omphizumab; the clinical outcome of nasal polyp improvement of a CRSwNP patient treated by omaszumab can be noninvasively predicted by virtue of the baseline expression level of any one of seven cell factors including Eotaxin, GM-CSF, CXCL-1, IP-10, IL-1a, MPO and IgE in nasal secretions of the patient, wherein the NPS improvement of the treatment improvement group and the poor treatment group is greater than that of the treatment improvement group and the poor treatment group is found for the first time. The clinical outcome of the nasal polyp improvement of the CRSwNP patient treated by omaszumab can be noninvasively predicted.

The invention belongs to the technical field of anti-tumor, and discloses application of HP and ICT combined anti-PD-1 inhibitor hydrogel in residual cancer recurrence after IRFA. The excellent drug delivery capacity of the hydrogel system is utilized, and the in-vivo local slow release effect of ICT and BMS202 can be remarkably amplified. Through synergistic treatment of the TAN and the MDSC, local and whole body adaptive immunoreactions can be efficiently activated, TAN is effectively reprogrammed to be in a tumor suppression type, infiltration of PMN-MDSC is reduced, and the conclusion is verified in a plurality of mouse tumor models in the chapter. Therefore, the HP (at) ICT / BMS provides a promising delivery strategy for improving the sensitivity of anti-PD-L1 treatment and efficiently preventing and treating latent residual cancer and metastasis after IRFA operation.

Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.

To provide pharmaceutical combinations of treating a clinical condition, e.g., AML.SOLUTION: A pharmaceutical combination comprising a DHODH inhibitor and an anti-CD38 therapeutic agent such as an anti-CD38 antibody is administered to a subject. The pharmaceutical combination can further comprise one or more additional therapeutic agents.SELECTED DRAWING: Figure 2D

The invention discloses an application of a T cell subset in improving the treatment effect of AK112. The T cell subset is XCL1 + CCL3 + CD8 + T cells. The invention relates to an application of a specific T cell subset in improving the curative effect of AK112, a T cell agonist and AK112 are combined for use, and by synergistically activating the T cell function and reversing the immunosuppression microenvironment, the single drug resistance of AK112 is effectively overcome, the continuous remission time is remarkably prolonged, the treatment response is deepened, the applicable patient group is expanded, and meanwhile, the toxicity risk is reduced. The invention further develops a full-spectrum flow cytometry kit containing 13 antibodies, 13 key markers of the T cell subgroup can be simultaneously detected by one tube, patients sensitive to evoximab treatment (i.e., high expression of the subgroup) can be efficiently screened out, and a convenient tool is provided for accurate medication.

The present disclosure provides methods of identifying a disease or condition suitable for treatment with dupilumab. The present disclosure also provides methods of identifying a subject having a disease or condition suitable for treatment with dupilumab. The present disclosure also provides methods of carrying out a clinical trial for dupilumab treatment of a disease or condition.

The present application relates to the role of UCK1 in promoting the sensitization of colorectal cancer treatment. The present application discloses the key role of UCK1 in the treatment of colorectal cancer. Clinical samples show that the expression of UCK1 in tumor tissues is reduced, and its low expression is related to chemotherapy resistance and poor prognosis. Studies have shown that UCK1 enhances the efficacy of oxaliplatin (OXA) by regulating metabolic pathways, and promotes B cell activation, thereby recruiting CD8 + T cells, and strengthens anti-tumor immunity. UCK1 overexpression can significantly improve OXA sensitivity and produce a synergistic effect with anti-PD-1 therapy. The present application proposes a new strategy centered on activating UCK1, providing a theoretical basis and application prospect for improving the response of colorectal cancer chemotherapy and immunotherapy.

The invention relates to the technical field of medicines, in particular to a composition and application thereof in preparation of antitumor medicines. The composition provided by the invention comprises the PD-1 monoclonal antibody and the emodin, and the emodin improves the anti-tumor function of T cells by improving phospholipid phosphatase secreted by CD8 + T cells. The anti-tumor curative effect of the emodin and the PD-1 monoclonal antibody in the composition is obviously higher than that of the two components which are independently administered, so that the emodin and the PD-1 monoclonal antibody synergistically improve the treatment effect of the PD-1 monoclonal antibody, and a novel treatment strategy is provided for clinical PD-1 monoclonal antibody drug resistance.

The present invention relates to the technical field of diagnostic markers, and in particular to a marker for evaluating the efficacy of PD-1 in treating melanoma and its application. Research conducted in the present invention has shown that extracellular vesicle PD-L2 is associated with the clinical response to anti-PD-1 therapy, and its changes are a more reliable biomarker for predicting the prognosis of melanoma patients receiving anti-PD-1 therapy. The baseline level of PD-L2 on the EV membrane and the dynamic changes of PD-L2 on the EV membrane can serve as predictors of the outcome of melanoma immunotherapy and play an important role in evaluating the prognostic effect.

The invention discloses a biliary duct cancer PD-1 monoclonal antibody treatment prognosis prediction system based on blood magnesium level, and relates to the technical field of biliary duct cancer immunotherapy prognosis, the biliary duct cancer PD-1 monoclonal antibody treatment prognosis prediction system comprises four core modules, a blood magnesium detection module uses a full-automatic biochemical analyzer to detect serum magnesium, the serum magnesium is divided into a low magnesium group and a normal blood magnesium group, and synchronous quality control is performed; the clinical data acquisition module acquires multi-dimensional information, and two persons check and complement data; the prognosis analysis module integrates data, and evaluates prognosis through statistical test, survival analysis and subgroup verification; and the result output module generates an encrypted report, visually presents and synchronizes the encrypted report to the electronic medical record system. The serum magnesium is used as a prediction index, the cost is low, the serum magnesium is easy to obtain, the serum magnesium is adaptive to hospital equipment at all levels, the independent prediction value and subgroup consistency are confirmed through rigorous analysis, prognosis can be dynamically updated, individualized suggestions are generated, prediction accuracy and clinical practicability are improved, and biliary duct cancer immunotherapy precision is promoted.

All currently available treatment options for autoimmune encephalitis such as anti-NMDAR encephalitis and anti-LGI1 encephalitis carry substantial potential safety risks. Further, no approved therapies exist for anti-NMDAR encephalitis and anti-LGI1 encephalitis. The invention provides a means for a treatment for autoimmune encephalitis (AIE) such as NMDAR encephalitis and anti-LGI1 encephalitis, comprising an IL-6 inhibitor such as anti-IL-6 receptor antibody or antigen binding fragment thereof.

To provide a high immunogenicity anti Aβ vaccine while maintaining an excellent safety profile.SOLUTION: A liposome vaccine composition includes a peptide antigen derived from β-amyloid (Aβ) presented on a surface of a liposome. The vaccine composition further includes a peptide including a universal T-cell epitope encapsulated into the liposome. The vaccine composition also may form a part of the liposome, and includes an adjuvant that may be at least partially presented on the surface of the liposome. The vaccine compositions are used for treating or preventing a disease or a condition related to amyloid beta, or symptoms characterized in loss of cognitive memory ability of a subject or a condition related thereto, inducing protective immune response to the symptom, or alleviating the symptoms. The vaccine composition may be provided as a kit. A related method for producing a liposome vaccine composition is also provided.SELECTED DRAWING: None

Provided herein are compositions and methods for treating spinal cord injury using nasal administration of anti-CD3 antibodies, e.g., foralumab.

The invention discloses a biomarker combination for predicting the curative effect of Evoximab on non-small cell lung cancer and application of the biomarker combination. The biomarker combination comprises NLR, MLR, PLR, ApoE and PD-L1. By integrating conventional blood indexes such as ApoE (participating in lipid metabolism regulation and immune regulation) and NLR (reflecting the whole body inflammation state), a non-invasive and clinically-popularized Evoximab curative effect prediction model is constructed, and the bottleneck problem of biomarker deficiency in bispecific antibody (Evoximab) treatment is solved. And a scientific basis is provided for accurately screening benefited crowds.

Methods and apparatus disclosed treat pain and mobility impairments by applying controlled subatmospheric pressure to skin over muscle tissue or joints during volitional muscle contractions against adaptive therapist resistance. Domes with basal openings sealing against skin perimeters, are evacuated to 13-90% of atmospheric pressure. Some embodiments have 3-10 second contraction intervals repeated at least three times per subatmospheric treatment cycle, before pressure is ramped to ambient pressure over at least 2 seconds. Results are improved range of motion, muscle strength, and pain reduction. Apparatus embodiments include vacuum manifolds, sensors for pressure and tissue distension, and optional integrated electrodes for performing TENS / STIM.

The present invention relates to methods of treating head and neck squamous cell carcinoma (HNSCC), such as metastatic or advanced HNSCC, in a subject in need thereof, comprising administering a therapeutically effective amount of an antibody to the subject, wherein the antibody specifically binds epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met) in addition to a PD-(L)1 axis inhibitor (pembrolizumab) and a platinum-based chemotherapy agent (carboplatin). In particular, the EGFR / c-Met antibody is amivantamab.

The invention discloses a device for treating osteoporosis by compounding electromagnetic field and ultrasonic wave with Disumab, which comprises a base plate, a support bed mattress plate is fixedly mounted on the upper surface of the base plate, a limiting groove is formed in the base plate, and a transmission assembly is movably arranged in the limiting groove. A medicine conveying module, an electromagnetic field generating module and an ultrasonic wave generating module are fixedly arranged on the surface of the transmission assembly, the medicine conveying module, the electromagnetic field generating module and the ultrasonic wave generating module are electrically connected with an external control module, and a display interaction module is arranged in the external control module; the electromagnetic field, ultrasonic waves and medicine assistance are combined, the synergistic effect of multiple treatment means is achieved, the treatment effect on osteoporosis is improved, and compared with a single treatment mode, the bone mineral density can be more rapidly and effectively increased, and the treatment period can be shortened.

The present invention provides methods for desensitizing patients in need of organ transplantation. Patients sensitized to human leukocyte antigens awaiting incompatible kidney transplantation have been treated with clazakizumab to show reduced or eliminated donor-specific antibody levels and improved transplantation rates. The present invention provides clazakizumab and variants for use in various embodiments of the method. In some embodiments, clazakizumab or its variants are administered simultaneously or sequentially with intravenous immunoglobulin.

Provided herein are compositions and methods for treating spinal cord injury using nasal administration of anti-CD3 antibodies, e.g., foralumab.

The present disclosure relates to methods of treating giant cell arteritis (GCA) using an IL-17 antagonist (e.g., Jukoulikumab). Also disclosed herein are uses of IL-17 antagonists (e.g., IL-17 antibodies, such as Jiukumab) for the treatment of GCA patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

To provide methods for treating psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), e.g., non-radiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS).SOLUTION: Methods are provided for treating PsA or axSpA using an IL-17 antagonist, such as an IL-17 antibody, such as secukinumab. Also provided herein are methods for inhibiting the progression of structural damage in PsA and axSpA patients using IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab.SELECTED DRAWING: None

The invention belongs to the technical field of brain glioma markers, and particularly relates to application of IGFBP2 in diagnosis and immunotherapy of glioblastoma. According to the invention, single cell sequencing data analysis reveals that CD47 in GBM is closely associated with an anoxic microenvironment, and meanwhile, it is proved that combined application of the anti-IGFBP2 and anti-CD47 antibodies can significantly improve the curative effect of CD47 targeted therapy. According to the research, the IGFBP2 is determined as a potential biomarker for predicting the anti-CD47 treatment response of the GBM patient for the first time, and a new thought is provided for overcoming the anti-CD47 drug resistance through a combined treatment strategy.

Methods for correlating a genetic variant with intraretinal fluid as a marker of response to anti-VEGF therapy in age-related macular degeneration (AMD). Further methods for correlating a genetic variant with visual acuity, anatomical outcomes, or treatment frequency are disclosed herein. The genetic variants identified were found in a non-gene region on the X chromosome p.22.3 in the MICOM gene in the NTRK3 gene and in the ANK2 gene.

According to the invention, 22 related genes of lactic acid metabolism are analyzed and researched, the 22 related genes are divided into 3 ovarian cancer subgroups, and immune cells, tumor purity, stromal cells and the like infiltrated by the 3 ovarian cancer subgroups in a tumor microenvironment are obviously different and have statistical differences. On the basis, a neural network algorithm is introduced, 22 lactic acid modified genes are used as prediction indexes, and a prediction model is established to evaluate the sensitivity degree of an ovarian cancer patient in receiving anti-PD-1 treatment. For example, 22 related genes of lactic acid metabolism mentioned in the invention are collected and arranged from previous literatures and reports, and are derived from a medical library (pubard, website: https: / / pubmec.ncbi.nlm.nih.gov / ) subordinate to the National Institute of Health, 'lactate / lactation 'is used as a keyword to search, and queried related researches are manually filtered and screened. According to the present invention, the 22 lactic acid modification genes comprise STC1, PLOD2, VCAN, HBB, SLC2A3, ATF3, DUSP1, AURKA, RRM2, SLC1A4, TXNIP, HELLS, NFS1, ABCC1, SLC16A3, SLC5A8, SLC5A12, NDRG3, HIF1A, LDHA, LDHB and SLC16A1;

The invention relates to an acinetobacter baumannii bacteriophage and application thereof, the acinetobacter baumannii bacteriophage is named PE65, the preservation number of the acinetobacter baumannii bacteriophage is CGMCC NO.46172, the acinetobacter baumannii bacteriophage is preserved in China General Microbiological Culture Collection Center on August 16, 2024, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the postcode is 100101; the invention has the advantages of obvious antibacterial effect, simple fermentation, low cost and good biological safety, and provides a safe and efficient alternative antibody treatment scheme for acinetobacter baumannii infected patients.

The present disclosure provides compositions and methods directed to anti-CD99 CAR-T therapies for treating cancer, such as DIPG. Ewing Sarcoma, and AML.

To provide a method for predicting treatment responsiveness in a cancer patient who receives treatment with an anti PD-1 antibody (especially, Nivolumab).SOLUTION: Provided is a method for predicting in vitro the responsiveness of a subject to an anti PD-1 antibody, and the method includes: a measurement step of measuring the amount of VEGF-A121 protein and the amount of VEGF-A165 protein in a sample derived from the subject; and a prediction step of predicting the responsiveness of the subject to treatment with the anti PD-1 antibody, on the basis of a ratio calculated from the measured amounts of two types of protein.SELECTED DRAWING: Figure 7D

Described herein is an automated neurocognitive training method and system for extending the alleviation of treatment-resistant psychiatric disorders. An exemplary method includes administering a drug having an antidepressant effect to a patient, and administering a neurocognitive training protocol to the patient during a critical period after administration of the drug. Furthermore, administering the neurocognitive training protocol to the patient includes providing the patient with a plurality of automated neurocognitive training sessions using a computing device. During each of the automated neurocognitive training sessions, a plurality of conditioning sequences are presented to the patient, each conditioning sequence including a respective non-self-related stimulus and a respective self-related stimulus.